Leland J Yee

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10104239/publications.pdf

Version: 2024-02-01

361413 395702 1,573 36 20 33 citations h-index g-index papers 36 36 36 2264 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients. Journal of Hepatology, 2016, 64, 773-780.	3.7	223
2	Interleukin 10 polymorphisms as predictors of sustained response in antiviral therapy for chronic hepatitis C infection. Hepatology, 2001, 33, 708-712.	7.3	173
3	Impact of longâ€ŧerm tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B. Cancer, 2015, 121, 3631-3638.	4.1	173
4	Risk Among Men Who Have Sex With Men in the United States: A Comparison of an Internet Sample and a Conventional Outreach Sample. AIDS Education and Prevention, 2002, 14, 41-50.	1.1	105
5	Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load. Hepatology, 2013, 58, 505-513.	7.3	104
6	Associations between serum lipids and hepatitis C antiviral treatment efficacy. Hepatology, 2010, 52, 854-863.	7.3	71
7	Association of CTLA4Polymorphisms with Sustained Response to Interferon and Ribavirin Therapy for Chronic Hepatitis C Virus Infection. Journal of Infectious Diseases, 2003, 187, 1264-1271.	4.0	62
8	Sexual and alcohol risk behaviours of immigrant Latino men in the Southâ€eastern USA. Culture, Health and Sexuality, 2009, 11, 17-34.	1.8	57
9	Long-term clinical outcomes in cirrhotic chronic hepatitis B patients treated with tenofovir disoproxil fumarate for up to 5Âyears. Hepatology International, 2015, 9, 243-250.	4.2	52
10	Tenofovir disoproxil fumarate (TDF) vs. emtricitabine (FTC)/TDF in lamivudine resistant hepatitis B: A 5-year randomised study. Journal of Hepatology, 2017, 66, 11-18.	3.7	52
11	Association of single nucleotide polymorphisms in interferon signaling pathway genes and interferon-stimulated genes with the response to interferon therapy for chronic hepatitis C. Journal of Hepatology, 2008, 49, 184-191.	3.7	49
12	Tropomyosin isoform 5b is expressed in human erythrocytes: implications of tropomodulin-TM5 or tropomodulin-TM5b complexes in the protofilament and hexagonal organization of membrane skeletons. Blood, 2000, 95, 1473-1480.	1.4	47
13	Tropomodulin-Binding Site Mapped to Residues 7–14 at the N-Terminal Heptad Repeats of Tropomyosin Isoform 5. Archives of Biochemistry and Biophysics, 2000, 378, 16-24.	3.0	47
14	Influence of ILâ€10RA and ILâ€22 polymorphisms on outcome of hepatitis C virus infection. Liver International, 2007, 27, 1134-1143.	3.9	45
15	Characteristics of a Sample of Men Who Have Sex with Men, Recruited from Gay Bars and Internet Chat Rooms, Who Report Methamphetamine Use. AIDS Patient Care and STDs, 2007, 21, 575-583.	2.5	38
16	Correlates of hepatitis B vaccination in a high-risk population: an internet sample. American Journal of Medicine, 2001, 110, 628-632.	1.5	35
17	HLA-B, -DRB1/3/4/5, and -DQB1 gene polymorphisms in human immunodeficiency virus-related Kaposi's sarcoma. Journal of Medical Virology, 2005, 76, 302-310.	5.0	26
18	Risk factors for acquisition of hepatitis C virus infection: a case series and potential implications for disease surveillance. BMC Infectious Diseases, 2001, 1, 8.	2.9	24

#	Article	IF	CITATIONS
19	Using Community-Based Participatory Research to Develop a Chat Room-Based HIV Prevention Intervention for Gay Men. Progress in Community Health Partnerships: Research, Education, and Action, 2007, 1, 175-184.	0.3	24
20	Genomic organization of mouse and human erythrocyte tropomodulin genes encoding the pointed end capping protein for the actin filaments. Gene, 2000, 256, 271-281.	2.2	23
21	Factors Associated With Testing for Hepatitis C in an Internet-Recruited Sample of Men Who Have Sex With Men. Sexually Transmitted Diseases, 2001, 28, 515-520.	1.7	18
22	Increasing Hepatitis B Vaccination among Young African-American Men Who Have Sex with Men: Simple Answers and Difficult Solutions. AIDS Patient Care and STDs, 2002, 16, 519-525.	2.5	15
23	Comparing MSM in the Southeastern United States who participated in an HIV prevention chat room-based outreach intervention and those who did not: how different are the baseline HIV-risk profiles?. Health Education Research, 2007, 23, 180-190.	1.9	15
24	Condom Acquisition and Preferences within a Sample of Sexually Active Gay and Bisexual Men in the Southern United States. AIDS Patient Care and STDs, 2007, 21, 861-870.	2.5	15
25	Review article: switching patients with chronic hepatitis B to tenofovir alafenamide—a review of current data. Alimentary Pharmacology and Therapeutics, 2022, 55, 921-943.	3.7	14
26	C-C Chemokine Receptor 2 and C-C Chemokine Receptor 5 Genotypes in Patients Treated for Chronic Hepatitis C Virus Infection. Immunologic Research, 2002, 26, 167-176.	2.9	13
27	Myxovirus-1 and protein kinase haplotypes and fibrosis in chronic hepatitis C virus. Hepatology, 2007, 46, 74-83.	7.3	11
28	Hepatitis A vaccination among young African American men who have sex with men in the deep south: psychosocial predictors. Journal of the National Medical Association, 2003, 95, 31S-36S.	0.8	10
29	Polymorphism in the Human Major Histocompatibility Complex and Early Viral Decline during Treatment of Chronic Hepatitis C. Antimicrobial Agents and Chemotherapy, 2009, 53, 615-621.	3.2	9
30	Host Genetics, Steatosis and Insulin Resistance among African Americans and Caucasian Americans with Hepatitis C Virus Genotype-1 Infection. Intervirology, 2009, 52, 49-56.	2.8	8
31	Tenofovir disoproxil fumarate in Asian or Pacific Islander chronic hepatitis B patients with high viral load (≥ 9 log ₁₀ copies/ml). Liver International, 2015, 35, 422-428.	3.9	6
32	Life course epidemiology and infectious diseases. International Journal of Epidemiology, 2002, 31, 300-301.	1.9	6
33	Using hepatitis A and B vaccination as a paradigm for effective HIV vaccine delivery. Sexual Health, 2007, 4, 121.	0.9	2
34	Genetic diversity in the major histocompatibility complex and the immune response to infectious diseases., 2003,, 77-116.		1
35	24 weeks of interferon-ribavirin therapy should not routinely be given to all hepatitis C patients. American Journal of Gastroenterology, 2002, 97, 497-498.	0.4	0
36	Reply. Hepatology, 2014, 59, 2427-2427.	7.3	0